Home・Elenco Azioni・Arcus Biosciences Inc

Arcus Biosciences Inc

Aperta

SettoreSettore sanitario

28.81 4.42

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

27.39

Massimo

28.58

Metriche Chiave
By Trading Economics
Entrata	-22M -128M
Vendite	-16M 17M
EPS	-1.02
Margine di Profitto	-752.941
Dipendenti	601
EBITDA	-42M -123M

Raccomandazioni
By TipRanks
Raccomandazioni	Fortemente da comprare
Previsioni per 12 mesi	+39.86% upside

Dividendi
By Acuity
Utili prossimi	5 ago 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	229M 3.5B
Apertura precedente	24.39
Chiusura precedente	28.81

Notizie sul Sentiment di mercato

By Acuity

79%

21%

307 / 340 Classifica in Healthcare

Arcus Biosciences Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

3 ago 2026, 19:36 UTC

Arcus Biosciences shares are lower today, reflecting broader market dynamics and geopolitical developments impacting investor sentiment. Earlier, shares peaked before declining.

31 lug 2026, 23:16 UTC

Arcus Biosciences Inc. shares are lower in after-market hours, continuing a trend of declining prices and remaining below the 20-day moving average.

30 lug 2026, 18:03 UTC

Arcus Biosciences Inc gains today, supported by a broader market uptick despite geopolitical tensions and inflation concerns. Shares pulled back from earlier session highs.

29 lug 2026, 19:56 UTC

Macro Event

Arcus Biosciences shares are lower amid broader market pressures from steady interest rates and rising crude oil prices, marking five consecutive sessions of decline.

28 lug 2026, 20:06 UTC

Arcus Biosciences Inc shares are lower today, reflecting broader market trends and declines in Asian markets, including significant losses in the Nikkei 225 Index.

27 lug 2026, 21:01 UTC

Arcus Biosciences Inc shares declined in after-market hours, continuing a downward trend over the last four sessions. No specific news was identified to explain the move.

24 lug 2026, 19:06 UTC

News

Arcus Biosciences has signed a clinical supply agreement with AVEO to evaluate casdatifan with tivozanib. Shares are trading lower, reflecting unusual weakness.

22 lug 2026, 20:13 UTC

Arcus Biosciences shares are higher in after-market hours. Broader market volatility is influenced by rising crude oil prices and geopolitical tensions.

21 lug 2026, 19:36 UTC

Arcus Biosciences shares are higher today, supported by overall market strength and positive sentiment in the biotechnology sector. The stock has advanced notably since Monday.

20 lug 2026, 18:06 UTC

News

H.C. Wainwright raised Arcus Biosciences' price target to $45 from $32, maintaining a Buy rating. Shares are higher today following the analyst's upgrade.

Confronto tra pari

Modifica del prezzo

Arcus Biosciences Inc Previsione

Obiettivo di Prezzo

By TipRanks

39.86% in crescita

Previsioni per 12 mesi

Media 38.63 USD 39.86%

Alto 47 USD

Basso 22 USD

Basato su 9 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Arcus Biosciences Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

9 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 9 che hanno fornito valutazioni azionarie a Arcus Biosciences Inc - Dist negli ultimi 3 mesi.

Sentiment

By Acuity

307 / 340 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Arcus Biosciences Inc

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California.